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This report highlights presentations made at
the Biomedical Research and the Environment
Conference held 1–2 November 1999 at the
Natcher Conference Center, National
Institutes of Health, Bethesda, Maryland, by
the Committee on Environmental Economics
in Biomedical Research and Products
Development and Applying Environmental
Product Design to Biomedical Research.
The need to improve environmental
performance of the healthcare delivery system
has implications for attention at both the local
and national levels. For example, in 1998 the
American Hospital Association (AHA) and the
U.S. Environmental Protection Agency (EPA)
signed a Memorandum of Understanding, an
agreement to work together to dramatically
reduce solid waste and mercury from hospi-
tals and their allied healthcare facilities. To
support this agreement, the suppliers of med-
ical products will be called upon to provide
products with improved environmental pro-
files. Thus, medical product manufacturers
will need to consider environmental aspects
in their research and development (R&D)
processes, as well as in their manufacturing
processes. 
This report discusses how some forward-
thinking R&D organizations in the medical
products industry have embraced this envi-
ronmental challenge to ensure that their
products meet numerous regulatory and cus-
tomer requirements while providing safe, efﬁ-
cacious, and cost-effective medical products.
A speciﬁc goal of the committee was to pre-
sent methods that several R&D organizations
use to meet customer and regulatory require-
ments. 
These methods are referred to as environ-
mental product design (EPD). EPD is not
unique to the medical products field. It has
been used successfully in the electronics and
automobile industries to improve environ-
mental performance. This model, “pulling”
environmental attributes through the supply
chain and the manufacturing system, can be
applied in the healthcare delivery system.
The Healthcare Sector 
and the Environment
The environmental effects of the healthcare
industry came into public consciousness dra-
matically in 1987 when reports of medical
waste washing up on public beaches was
reported by national news. Since that time,
attention to the medical sector by grassroots
environmentalists and environmental regula-
tors has increased considerably. In addition,
EPA has named medical waste incinerators
the fourth largest source of mercury in the
environment (1) and also a major source of
dioxin (2). In 1999 EPA promulgated new
and controversial emissions standards for
medical waste incinerators (3).
With this activity has come increased
attention to mercury in general, which has
been a focus of the Great Lakes U.S.–Canada
Binational Toxics Strategy (4), the 1998 EPA
“Action Plan for Mercury” (5), and the EPA
“Persistent, Bioaccumulative, and Toxic
Chemicals Initiative” (6). New England gov-
ernors and eastern Canadian premiers have
agreed to aggressively reduce mercury use and
emissions in that region (7), and many New
England states are considering ambitious leg-
islation to require the labeling of mercury
products and reduction of mercury use (8).
At the same time, various grassroots efforts
have evolved to push for implementation of
the regulations and other environmental
improvements.
Hospitals have also been facing increasing
financial pressures and escalating waste dis-
posal bills. Many hospitals have found they
could save money through waste reduction
and have used this opportunity to create
excellent environmental programs that reduce
or eliminate mercury use, institute recycling
programs, and strictly segregate infectious
waste to reduce its volume.
A major outcome of this interest in
environmental effects of the healthcare indus-
try is the current partnership between the
AHA and EPA. In 1998 the AHA and EPA
signed a Memorandum of Understanding
agreeing to work together to virtually elimi-
nate mercury waste and to dramatically reduce
solid waste coming from healthcare facilities.
Activities resulting from the Memorandum of
Understanding , now called Hospitals for a
Healthy Environment, include planned semi-
nars to bring pollution prevention and waste
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minimization technology and knowledge to
hospitals across the country. The AHA plans
to collect information from their member
hospitals on the implementation of these
techniques and is developing an awards
program to honor hospitals that excel in
environmental programs.
Environmentally Preferable
Purchasing
Hospitals continuously reviewing business
expenses have discovered savings opportunities
in waste management costs. In addition, the
Federal government and many state agencies
have been mandated to study environmental
issues in purchasing practices of hospitals.
Environment-conscious healthcare organiza-
tions are looking for products that reduce their
environmental and waste disposal costs, prod-
ucts without toxic or otherwise problematic
components or ingredients, and suppliers that
show a corporate environmental commitment
beyond meeting compliance and performance
standards. Consequently, medical product pro-
ducers are responding by improving the envi-
ronmental proﬁle of their products. 
Some healthcare purchasers are also
looking for suppliers who share their environ-
mental commitment and vision. This commit-
ment can be demonstrated by having a strong
environmental record both here and abroad,
continually improving the environmental per-
formance of the product and its packaging,
and responding to environmental needs of the
customers. Products that help the facility
reduce environmental and waste disposal costs
include those with reduced packaging or fewer
toxic constituents and products that conserve
energy and water. Products with mercury,
other persistent bioaccumulative toxins, or, in
some cases, polyvinyl chloride (PVC) cannot
meet the needs of an environmentally
conscious purchaser. 
Many healthcare delivery organizations
have begun to look at environmental attrib-
utes in their purchasing, especially in terms of
energy efficiency. Some organizations have
made environmental excellence part of their
mission and have translated this into their
purchasing policies. Catholic Healthcare
West (CHW), for instance, has committed
itself to the principles of the Coalition for
Environmentally Responsible Economies
(CERES) (9). This commitment has been
extended to its suppliers. CHW included
environmental values into its written agree-
ment with Premier, a group-purchasing orga-
nization. Premier has agreed, as part of its
relationship with CHW, to support CERES,
the Health Care Without Harm campaign,
(10) and reduction of the volume and toxicity
of the medical waste stream. Premier has also
agreed to assist CHW in identifying products
containing mercury and PVC, to consider the
environmental impact of a product or service
for which it contracts, and to communicate
the desire for environmentally favorable prod-
ucts to manufacturers (11).
Kaiser Permanente has also made a
commitment to improving its environmental
bottom line. Kaiser states in its requests for
proposals that it will be
demonstrating a preference for products
that cause the least amount of environ-
mental harm during manufacturing, use,
and disposal in partnering with suppliers
who demonstrate a commitment to envi-
ronmental quality through their business
practices. (12)
Kaiser determined that latex gloves often
caused allergies in its employees and that the
environmental attributes of latex were worse
than those of nitrile (13).
The Boston area hospitals served by the
Massachusetts Water Resource Authority
water treatment facility have been under
much regulatory pressure to reduce mercury
in their wastewater discharge. These hospitals
have stopped buying certain products and
brands that tested positive for mercury. This
list is available as a public database to help
hospitals identify products containing
mercury (14).
These efforts form the beginning of envi-
ronmental purchasing for healthcare organi-
zations. As environmental demands on
hospitals increase and more public awareness
encourages hospitals to be proactive in their
environmental programs, healthcare environ-
mental purchasing will mature. Expectations
of the environmental value of products will
increase, and suppliers and manufacturers will
need to look for efficient ways to determine
the environmental needs and values of their
customers and incorporate these features into
the products they offer. Incorporating cus-
tomer needs at the R&D level is crucial to the
success of ultimately bringing environmental
attributes to the product because it is most
efficient to consider production changes at
this stage. Manufacturers able to position
themselves to meet the environmental speciﬁ-
cations of healthcare purchasers will be at an
advantage in the marketplace. 
Regulation of the
Pharmaceutical Industry
EPA has worked with the pharmaceutical
industry to encourage and implement pollu-
tion prevention measures through waste min-
imization, identification of waste streams,
optimization of process trains, and solvent
reuse and recovery. A variety of pollution pre-
vention measures are available to pharmaceu-
tical manufacturers, including material
substitution in tablet coating and equipment
cleaning methods, process modifications in
transfer operations and batch or continuous
operations, and process optimization.
Pharmaceutical manufacturers can also imple-
ment in-process recycling or other recovery
and reuse methods to reduce the quantity of
hazardous waste. Additionally, under the
pharmaceutical MACT standard (15), EPA
rewards pollution prevention in some cases by
allowing it as an alternative to the more tradi-
tional end-of-pipe controls. Many of these
techniques have been documented in the
EPA Office of Compliance publication
“Proﬁle of the Pharmaceutical Industry” (16).
EPA also regulates the pharmaceutical
industry through a number of Federal laws,
including the Clean Air Act (17), the Clean
Water Act (18), the Resource Conservation
and Recovery Act (19), the Safe Drinking
Water Act (20), the Underground Storage
Tank regulations (21), the Emergency
Planning and Community Right-to-Know
Act (22), and the Toxic Substances Control
Act (23). The pharmaceutical industry is
unique when compared to most EPA-
regulated industries because of its low ratio of
finished product to raw material input, the
quantities of residual waste created, and the
generation of particular wastes including
equipment cleaning residues, reaction
residues, and spent solvents and reactants. 
The U.S. Food and Drug Administration
(FDA) regulates the pharmaceutical industry
through the Federal Food, Drug, and
Cosmetic Act (24). Five centers within the
FDA deal with FDA-regulated products: the
Center for Drug Evaluation and Research
(CDER), the Center for Biologics Evaluation
and Research, the Center for Veterinary
Medicine, the Center for Devices and
Radiological Health, and the Center for Food
Safety and Applied Nutrition. Marketing a
new drug entails an involved application
process, including preclinical trials, an
Investigational New Drug application to the
FDA, three phases of clinical trials, a New
Drug application, and postapproval testing.
Supporting materials must accompany the
applications, and companies spend millions
of dollars and many years on this process on
each drug before it is ﬁnally marketed to the
public (25).
The mission of the CDER of the FDA is
to ensure that safe and effective drugs are
available to the American public. CDER has
integrated the consideration of the environ-
mental impacts of approving drug product
applications into its regulatory process in
accordance with the National Environmental
Policy Act of 1969 (26), which requires all
Federal agencies to assess the environmental
impacts of their actions. This environmental
review focuses on the environmental impacts
of consumer use and disposal of drugs for
human use.
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After the FDA approves a drug product
application, an applicant may wish to make
changes in the manufacture, processing, or
packing of the drug substance or drug prod-
uct for technical, economic, or environmen-
tal reasons. An applicant is required to notify
the FDA about each change in each condi-
tion established in an approved application
beyond the variations already provided for in
the application. Depending on the type of
change, the applicant notifies the FDA by
a) a supplement requiring FDA approval
before the change is made; b) a supplement
submitted at least 30 days prior to distribu-
tion of the product made with the change;
c) a supplement for changes that may be put
into effect immediately upon FDA receipt of
the supplement, or d ) an annual report.
Changes in solvent, formulation, sources of
plants/animals for drugs, and packaging are a
few examples of the types of changes that
may be contemplated for environmental rea-
sons. These changes will likely result in sup-
plement applications to the FDA for
approval before implementation. 
The extensive requirements of the FDA
to report and provide data to support
changes should be considered in the R&D of
the drug, because postapproval changes can
be costly in both the time and money. Most
healthcare product R&D organizations are
future oriented and are not inclined to
review products already in the marketplace.
Through careful consideration of the envi-
ronmental implications of the manufactur-
ing, processing, and packing of a drug in the
R&D product stage, costly postapproval
changes can be avoided.
How R&D Organizations of
Medical Products Companies
Have Responded
The R&D units of medical product compa-
nies have been focused on providing safe and
efficacious products to meet the healthcare
needs of the public. This imperative remains
the foremost mission for pharmaceutical and
medical device companies. The requirements
for new products entering the healthcare
delivery system, however, are more complex
than the need for safety and efﬁcacy. Medical
products companies understand that to
remain competitive they must respond com-
prehensively to the needs of their customers.
Cost and environmental attributes have sur-
faced as new, unmet requirements of the
healthcare delivery system. The cost of health-
care products is outside the scope of this com-
mittee. However, it is widely understood that
waste reduction, including environmental
waste, results in expense reduction beneﬁts.
Many concerned medical product
manufacturing companies are responding to
the changing environmental requirements of
their customers while they remain focused on
their original (safe and efficacious) mission
and regulatory requirements. Presented below
are various models used successfully by orga-
nizations to meet regulatory and client expec-
tations and to improve the environmental
proﬁle of their products. 
a) Baxter International, Inc. develops,
distributes, and manufactures a variety of
products, systems, and services used in the
healthcare ﬁeld. Hospitals, clinical and med-
ical research laboratories, blood and dialysis
centers, and doctors’ ofﬁces in over 100 coun-
tries use these products for a wide range of
clinical procedures. Baxter has manufacturing
facilities in 28 countries. 
The company routinely reports their
progress toward achieving sustainability tar-
gets, in large measure focused on the environ-
mental impact of their products in the
healthcare system. Baxter reports that it has
reduced its packaging by 4% since 1995 and
still hopes to reach its goal of 20% reduction
by 2005 (27).
Baxter has worked on customer-oriented
environmental issues since 1992, employing a
checklist and life-cycle approach in their new
product development process. The company’s
EPD reviews choice of product materials,
supplier issues, packaging, environmental
impact of manufacturing, and customer use
and disposal of the product.
b) Bristol-Myers Squibb (BMS) is a health
and personal-care company manufacturing
medicines, medical devices, nutritionals, and
beauty care items. BMS has facilities in over
60 countries and had revenues of over $18
billion in 1998. BMS applies the principles of
product life cycle (PLC) to ensure that new
products include environmental qualities
while minimizing waste throughout the prod-
uct’s manufacture, use, and disposal. PLC at
BMS employs cross-functional, multidiscipli-
nary teams who review the product as it
moves through R&D to commercialization.
The company considers PLC a business tool
that results in environmentally optimal prod-
ucts and reduces cost. Additionally, the com-
pany recognizes that the market, especially
BMS customers, is demanding products with
improved environmental profiles. In consid-
ering environmental features in the R&D
stage, the cost of changing products in the
market is avoided.
The PLC process at BMS begins with
identifying critical environmental health and
safety issues at each stage of the product life
cycle. These issues include the environmental
impacts of the product (including manufac-
turing, distribution, use, and disposal) on the
air, water, and land through waste disposal.
Opportunities to minimize these effects are
prioritized using a cost-benefit approach.
This produces a set of recommendations con-
sidered for product ingredients, manufactur-
ing processes, packaging, and best disposal
practices. (Table 1).
Current strategies at BMS include waste
minimization and pollution prevention pro-
grams, toxic solvent reduction, and optimiza-
tion of emerging environmentally acceptable
technologies. For package designers this
means reducing packaging to lower costs;
using recyclable or environmentally benign
packaging; considering alternative packaging
that offers environmental advantages of the
standard options; using soy- or vegetable-
based inks; and educating customers on recy-
cling and disposal options. In manufacturing,
PLC requires consideration of the environ-
mental health and safety impact of raw mate-
rials, manufacturing processes, and regulatory
impacts at the facility. For the marketing
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Table 1. Enhancing products through product life-cycle analysis. 
Environmental Research and  Sales, distribution,  Consumer  Final
product proﬁling product development Marketing  Manufacturing  Packaging  transportation use  disposition
Research and development • • • • • •
Marketing and sales • • • • • • •
Engineering • • • • •
Production planning • • • •
Purchasing • • • • •
Production • • •
Plant management • • • •
Quality assurance • • • • • •
Maintenance • • • •
Environmental health and safety • • • • • • •
Public relations • • • • • • •
Finance and accounting • • • • • •
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department the consideration of shelf space
and product appearance is balanced with the
resultant environmental impact. 
c) At SmithKline Beecham (SKB), a phar-
maceutical and healthcare company with
47,000 employees in 160 countries, EPD has
focused on improving chemical synthesis efﬁ-
ciencies to reduce waste and solvent use and
optimize energy requirements. SKB has char-
acterized this work as “green chemistry.”
Most of its pharmaceutical products are
chemically synthesized. The environmental
challenges for chemically synthesized, bulk
drug manufacturing processes are complex
molecules, complex synthetic routes, complex
processes and wastes, strong regulation by the
FDA, costly route and process changes post-
FDA approval, and the need for early and
rapid route deﬁnition.
To understand the environmental oppor-
tunities for improving chemical synthesis
processes, SKB developed a phased approach.
In Phase I the company identified mature
chemistries. These chemistries were broken
out into individual reaction steps. Each step
was categorized according to chemical
reaction types (e.g., oxidation, reduction). A
chemistries database was then established.
Tables 2 and 3 identify “greenness” metrics
for mass and energy as a means to character-
ize chemistry efﬁciencies.
In Phase II the company developed a
sustainability-driven assessment system and
applied it to the chemistries database. The
result was a database of chemistries ranked
and prioritized according to sustainability
qualities. Table 4 describes a comparison of
various chemistries based on these priorities. 
The company concluded that mass and
energy terms appeared to be good leading
indicators of overall environmental impact.
Additionally, explicit tracking of solvent use
is highly indicative of overall environmental
impact. The evaluation using their sustain-
ability metrics clearly differentiates between
chemistries and chemical processes.
d) Allergan is a pharmaceutical company
specializing in opthamological and dermata-
logical products sold in over 100 countries.
As a result of customer feedback indicating a
preference for products with less packaging
and minimal hazards, Allergan embarked on
an EPD project establishing evaluation
criteria to be integrated into the product
development process. Allergan assembled an
implementation team including internal
Allergan representatives from marketing,
R&D, packaging, environmental health and
safety, manufacturing, legal, and purchasing
departments, as well as external consultants
who had experience with design for the envi-
ronment and life cycle approaches to product
development. The team developed the envi-
ronmental evaluation criteria, the criteria use
instructions, an accountability structure, and
a process model for integration. The result-
ing system enables product designers to
investigate the potential environmental
impacts of different design options simply by
inputting values into the computer.
Implementation and training began in 1994
and was completed in 1995.
The quantitative method included two
aspects: product formulation and manufacture
based on materials, and packaging considera-
tions. A chemical list is included in the
method for evaluating the material environ-
mental impacts. The chemical list includes
references to threshold limit values, reportable
quantities, threshold planning quantities, haz-
ardous waste generation, Allergan-restricted
materials, carcinogenic materials, and govern-
ment reporting requirements. The packaging
considerations include evaluations against
Table 3. Greenness assessment—example of energy
metrics.
MJ, megajoule. 
Σ
Σ
     
        
solvent re ery energy MJ
mass of product kg
cov (
()
Σ
Σ
      
      
waste treatment energy MJ
mass of product kg
()
()
Σ
Σ
    
      
Process energy MJ
mass of product kg
()
()
Category
Energy
Table 2. Greenness assessment—example of mass metrics.
Units
% 
kg/kg
% 
kg/kg
kg/kg
kg/kg
kg/kg
kg/kg
Σ , summation. 
Σ       
    
mass solvent in kg
Mass of product kg
() ( )
()
Mass of product kg
mass solvent in kg
    
      
()
() ( ) Σ
Σ     
    
total mass kg
Mass of product kg
()
()
Σ           
    
total mass kg mass recyled solvent other kg
Mass of product kg
()−+ () ( )
()
Mass of product kg
total mass kg mass recyled solvent other kg
    
          
()×
()−+ () ( )
100
Σ
Mass of product kg
total mass kg
    
    
()×
()
100
Σ
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Mass
Table 4. Comparing chemistries. 
Units Knoevenagel Grignard Ether N-Acylation N-Alkylation Resolution Lithal
Σ total mass in excluding water (kg)
Mass of product (kg) 
kg/kg 6.4 12.7 16.0 18.9 20.8 24 30.1
Σ mass water (kg)
Mass of product (kg) 
kg/kg 1.0 6.1 14.4 11.3 14.3 23.5 6.4
Σ process energy (MJ)
Σ mass of product (kg)
MJ/kg 4.0 6.3 8 8.6 23 11.7 30.9
Σ total energy (MJ)
Σ mass of product (kg)
MJ/kg 9.0 16.7 14 24.4 39 50 62.1
Number of different solvents No 1.1 1.3 1.9 1.5 1.6 1 2.3
Overall estimated recovery efﬁciency % 86% 75% 32% 65% 68 68 58%
Solvent mass factor (gross mass solvent/mass product) kg/kg 4.7 10.6 11.8 16.5 16.5 20.4 25.9
Mass of solvent waste kg/kg  0.6 2.65 8 5.8 5.3 6.5 11
All atom efﬁciency % 78% 78 69% N/A 64% 30 59%
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Allergan-restricted materials, packaging weight
reductions, packaging levels reduction, pack-
aging recycled-content materials use, packag-
ing component recyclability, biodegradability
of packaging, and whether packaging compo-
nents are reusable by Allergan. 
The criteria have been used in the devel-
opment of three new products, and the prin-
ciples have been used in many other product
redesigns. The potential product, including
manufacturing component and packaging
component analysis, has a possible quantita-
tive score of 100. Table 5 exemplifies the
analysis of three products whose scores ranged
from 67 to 70 out of a possible 100. Areas
that scored low or not at all include reduc-
tions in packaging weights per unit, use of
recycled-content materials, reuse of packaging
materials by Allergan, and elimination of lev-
els of packaging.
Allergan has taken steps to integrate
environmental criteria into the product
design process. The initial completion of
worksheets for three new products indicates
that product improvement from an environ-
mental perspective can and will occur.
Raising the awareness of the product design-
ers at Allergan has not only improved the
environmental profile of new products but
has also been useful in improving existing
products, which consistently rank 20–40
points higher than older products.
Conclusion
Many pharmaceutical companies are already
incorporating environmental issues into
R&D processes in varied and creative ways.
The committee believes it is possible to create
a program (toolbox) that can assist all phar-
maceutical companies find the best method
of incorporating these ideas into their
processes. This program could guide a com-
pany from the beginning of the R&D phase
through ﬁnal FDA approval, facilitating deci-
sions on environmental questions and
options. It could also assist companies in
partnering with their customers to provide
products with the environmental attributes
most crucial to healthcare facilities. Working
together, the pharmaceutical industry can
lead the healthcare supply chain in bringing
environmental excellence to the entire health-
care delivery system.
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Product no. 1 Product no. 2 Product no. 3 high score
Product formulation and manufacture
Threshold limit value 10.0 8.0 10.0 10.0
Threshold planning quantity 5.0 5.0 5.0 5.0
Reportable quantity 5.0 4.0 5.0 5.0
Use of restricted materials 10.0 10.0 10.0 10.0
Generation of hazardous wastes 7.5 7.5 7.5 7.5
Use of carcinogens 7.5 7.5 7.5 7.5
Government reporting requirements 5.0 5.0 5.0 5.0
Subtotal 50.0 47.0 50.0 50.0
Packaging
Use of restricted materials 10.0 10.0 10.0 10.0
Weight reduction 0.0 0.0 0.0 10.0
Recycled content use 0.0 0.0 0.0 10.0
Allergan reusable packaging 0.0 0.0 0.0 5.0
Material recyclability 10.0 10.0 10.0 10.0
Packaging level elimination 0.0 0.0 0.0 5.0
Subtotal 20.0 20.0 20.0 50.0
Total 70.0 67.0 70.0 100.0
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